Table 3. Ongoing clinical trials of intraperitoneal chemotherapy in the prophylaxis of GC peritoneal metastases.

ClinicalTrials.gov Identifier	Country	Estimated enrollment	Status/start-completion date	IP chemotherapy regimen	Adjuvant systemic chemotherapy
Prospective randomized controlled trial
NCT00992199	China	79 participants	Unknown, August 2009–December 2011	Cisplatin 60 mg + 5-FU 1.0 g, once a week for 3 times	Data not available
NCT02205008	Korea	230 participants	Unknown, October 2012–November 2018	EPIC operation day: 0.9% saline solution 1 L plus mitomycin C 10 mg/m2	S-1: <1.25 m2, 40 mg; 1.25–1.5 m2, 50 mg; >1.5 m2, 60 mg
				1–4 postoperative day: 0.9% saline solution 1 L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq
NCT02269904	China	120 participants	Unknown, April 2014–June 2018	Fluorouracil implants 800 mg, implanted in the abdominal cavity during operation	XELOX: oxaliplatin 130 mg/m2 day 1, capecitabine 1,000 mg/m2 days 1–14, every 3 weeks for a total of 6 cycles

EPIC, early postoperative intraperitoneal chemotherapy; 5-FU, 5-fluorouracil; GC, gastric cancer; IP, intraperitoneal.